Company profile: Achillion Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies targeting the complement system, including Soliris for paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and neuromyelitis optica spectrum disorder; Ultomiris, a long-acting C5 complement inhibitor, for PNH, aHUS, generalised myasthenia gravis and NMOSD; and Strensiq for hypophosphatasia.
Products and services
- ULTOMIRIS: Long-acting, clinical-grade C5 complement inhibitor therapy that treats paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder
- SOLIRIS: Clinical-grade medication used to treat paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, and neuromyelitis optica spectrum disorder
- STRENSIQ: Clinical-grade enzyme replacement therapy for patients with hypophosphatasia (HPP), used in clinical care for disease management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Achillion Pharmaceuticals
Cellestis
HQ: Australia
Website
- Description: Provider of QuantiFERON products for medical diagnosis and scientific research, utilizing a patented whole blood method to detect cell-mediated immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestis company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
AN2 Therapeutics
HQ: United States
Website
- Description: Provider of boron chemistry–based drug discovery and clinical development for infectious diseases, including epetraborole, an oral therapy in development for chronic non-tuberculous mycobacterial lung disease targeting Mycobacterium avium complex, and conducting clinical trials to obtain regulatory approval for new medications for infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AN2 Therapeutics company profile →
Okogen
HQ: United States
Website
- Description: Provider of ophthalmic anti-infective drug candidates, including OKG-0303, a fixed-dose combination eyedrop for acute infectious conjunctivitis that combines an antiviral, ocular decongestant, and antibacterial; OKG-0301, an antiviral shown to inhibit viral replication in adenoviral conjunctivitis; and the RUBY trial evaluating the safety and efficacy of OKG-0301.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Okogen company profile →
F2G
HQ: United Kingdom
Website
- Description: Provider of novel antifungal drug discovery and development, advancing patented compounds and technologies to treat life-threatening fungal diseases. Founded on proprietary genomics technology (MycoBank) that identifies essential gene targets in fungi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F2G company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Achillion Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Achillion Pharmaceuticals
2.2 - Growth funds investing in similar companies to Achillion Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Achillion Pharmaceuticals
4.2 - Public trading comparable groups for Achillion Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →